Skip to main content

4 Result(s)

within H A Burris III Remove this filter

and

  1. Article

    Open Access

    Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

    We assessed the maximum tolerated regimen (MTR) and dose-limiting toxicities of pazopanib and lapatinib in combination with weekly paclitaxel, and the effect of pazopanib and lapatinib on paclitaxel pharmacoki...

    A R Tan, A Dowlati, M N Stein, S F Jones, J R Infante… in British Journal of Cancer (2014)

    Download PDF (213 KB) View Article

  2. Article

    Open Access

    Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

    We evaluated week-on/week-off axitinib dosing plus chemotherapy in patients with gastrointestinal tumours, including tumour thymidine uptake by fluorine-18 3′-deoxy-3′-fluorothymidine positron emission tomogra...

    C K Hoh, H A Burris III, J C Bendell, J Tarazi, B Rosbrook… in British Journal of Cancer (2014)

    Download PDF (584 KB) View Article

  3. No Access

    Article

    Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs

    Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which result...

    H A Burris III in Oncogene (2009)

  4. No Access

    Article

    A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

    Purpose: Ixabepilone is one of the epothilones, a new class of cytotoxics, that function as microtubule-stabilizing agents. With the primary endpoint of assessing ixabepilone’s response rate against metastatic ga...

    J. A. Ajani, H. Safran, C. Bokemeyer, M. A. Shah, H.-J. Lenz… in Investigational New Drugs (2006)